Page 24 - Cellular Imaging in Regenerative Medicine, Cancer and Osteoarthritis

Chapter 1
References
1. Bernsen MR, Kooiman K, Segbers M, van Leeuwen FW, de Jong M. Biomarkers in preclinical cancer imaging. Eur J Nucl Med Mol Imaging. 2015;42(4):579-96.
2. Meng Q, Li Z. Molecular imaging probes for diagnosis and therapy evaluation of breast cancer. Int J Biomed Imaging. 2013;2013:230487.
3. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clinical Radiology. 2010;65(7):500-16.
4. Chen Z-Y, Wang Y-X, Lin Y, Zhang J-S, Yang F, Zhou Q-L, et al. Advance of Molecular Imaging Technology and Targeted Imaging Agent in Imaging and Therapy. 2014;2014:1-12.
5. Weissleder R. Molecular Imaging: Principles and Practice: People’s Medical Publishing House; 2010.
6. Semmler W, Schwaiger M. Molecular Imaging I: Springer Berlin Heidelberg; 2008.
7. Semmler W, Schwaiger M. Molecular Imaging II: Springer Berlin Heidelberg; 2008.
8. Accomasso L, Gallina C, Turinetto V, Giachino C. Stem Cell Tracking with Nanoparticles for Regenerative Medicine Purposes: An Overview. Stem Cells International. 2016;2016:1-23.
9. Ruggiero A, Guenoun J, Smit H, Doeswijk GN, Klein S, Krestin GP, et al. In vivo MRI mapping of iron oxide-labeled stem cells transplanted in the heart. Contrast Media Mol Imaging. 2013;8(6):487-94.
10. Stacy MR, Sinusas AJ. Emerging Imaging Modalities in Regenerative Medicine. 2015;3(1):27-36.
11. Ruggiero A, Thorek DL, Guenoun J, Krestin GP, Bernsen MR. Cell tracking in cardiac repair: what to image and how to image. Eur Radiol. 2012;22(1):189-204.
12. Bernsen MR, Kooiman K, Segbers M, Van Leeuwen FWB, De Jong M. Biomarkers in preclinical cancer imaging. Eur J Nucl Med Mol I. 2015;42(4):579-96.
13. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. 2008;27(4):545-54.
14. Momcilovic M, Bailey ST, Lee JT, Zamilpa C, Jones A, Abdelhady G, et al. Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer. J Vis Exp. 2018(137).
15. Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer. 2013;49(8):1975-83.
16. Bodei L, Ambrosini V, Herrmann K, Modlin I. Current Concepts in68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies. Journal of Nuclear Medicine. 2017;58(11):1718-26.
17. Zandee WT, Brabander T, Blazevic A, Kam BLR, Teunissen JJM, Feelders RA, et al. Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2018.
18. Van Der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, et al. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol I. 2018.
19. van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: Radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. 2015;172(1):R1-8.
20. Chan HS, de Blois E, Morgenstern A, Bruchertseifer F, de Jong M, Breeman W, et al. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. PLoS One. 2017;12(7):e0181473.
21. Chan HS, Konijnenberg MW, De Blois E, Koelewijn S, Baum RP, Morgenstern A, et al. Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate. 2016;6(1).
22. Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJ, et al. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging. 2014;2:55-66.
23. Chatalic KL, Kwekkeboom DJ, de Jong M. Radiopeptides for Imaging and Therapy: A Radiant Future. J Nucl Med. 2015;56(12):1809-12.
22